StreetInsider.com News Articles

Immunovia announces determined exercise price for warrants series TO 3

Thu, 27 Mar 2025 16:26:00 -0400

LUND, Sweden, March 27, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 3 (the "warrants") has been determined to SEK 0.24. The exercise period for the warrants commences on 1 April 2025 and runs up to and including 15 April 2025. The last day for trading in the warrants is 11 April 2025.

Immunovia carried out a rights issue of units during August – September 2024 (the "Rights Issue"). Each unit issued in the

Immunovia announces determined exercise price for warrants series TO 3

Thu, 27 Mar 2025 16:26:00 -0400

Immunovia carried out a rights issue of units during August – September 2024 (the "Rights Issue"). Each unit issued in the

Immunovia announces determined exercise price for warrants series TO 3

Thu, 27 Mar 2025 16:26:00 -0400

Immunovia carried out a rights issue of units during August – September 2024 (the "Rights Issue"). Each unit issued in the

Immunovia announces determined exercise price for warrants series TO 3

Thu, 27 Mar 2025 16:26:00 -0400

Immunovia carried out a rights issue of units during August – September 2024 (the "Rights Issue"). Each unit issued in the

Immunovia announces determined exercise price for warrants series TO 3

Thu, 27 Mar 2025 16:26:00 -0400

Immunovia carried out a rights issue of units during August – September 2024 (the "Rights Issue"). Each unit issued in the

Immunovia announces determined exercise price for warrants series TO 3

Thu, 27 Mar 2025 16:26:00 -0400

Immunovia carried out a rights issue of units during August – September 2024 (the "Rights Issue"). Each unit issued in the

Immunovia announces determined exercise price for warrants series TO 3

Thu, 27 Mar 2025 16:26:00 -0400

Immunovia carried out a rights issue of units during August – September 2024 (the "Rights Issue"). Each unit issued in the

Immunovia announces determined exercise price for warrants series TO 3

Thu, 27 Mar 2025 16:26:00 -0400

Immunovia carried out a rights issue of units during August – September 2024 (the "Rights Issue"). Each unit issued in the

Immunovia announces determined exercise price for warrants series TO 3

Thu, 27 Mar 2025 16:26:00 -0400

Immunovia carried out a rights issue of units during August – September 2024 (the "Rights Issue"). Each unit issued in the

Immunovia announces determined exercise price for warrants series TO 3

Thu, 27 Mar 2025 16:26:00 -0400

Immunovia carried out a rights issue of units during August – September 2024 (the "Rights Issue"). Each unit issued in the

Immunovia announces determined exercise price for warrants series TO 3

Thu, 27 Mar 2025 16:26:00 -0400

Immunovia carried out a rights issue of units during August – September 2024 (the "Rights Issue"). Each unit issued in the

Immunovia announces determined exercise price for warrants series TO 3

Thu, 27 Mar 2025 16:26:00 -0400

Immunovia carried out a rights issue of units during August – September 2024 (the "Rights Issue"). Each unit issued in the

Immunovia announces determined exercise price for warrants series TO 3

Thu, 27 Mar 2025 16:26:00 -0400

Immunovia carried out a rights issue of units during August – September 2024 (the "Rights Issue"). Each unit issued in the

Immunovia announces determined exercise price for warrants series TO 3

Thu, 27 Mar 2025 16:26:00 -0400

Immunovia carried out a rights issue of units during August – September 2024 (the "Rights Issue"). Each unit issued in the

Immunovia announces determined exercise price for warrants series TO 3

Thu, 27 Mar 2025 16:26:00 -0400

Immunovia carried out a rights issue of units during August – September 2024 (the "Rights Issue"). Each unit issued in the

Immunovia announces determined exercise price for warrants series TO 3

Thu, 27 Mar 2025 16:26:00 -0400

Immunovia carried out a rights issue of units during August – September 2024 (the "Rights Issue"). Each unit issued in the

Immunovia announces determined exercise price for warrants series TO 3

Thu, 27 Mar 2025 16:26:00 -0400

Immunovia carried out a rights issue of units during August – September 2024 (the "Rights Issue"). Each unit issued in the

Immunovia announces determined exercise price for warrants series TO 3

Thu, 27 Mar 2025 16:26:00 -0400

Immunovia carried out a rights issue of units during August – September 2024 (the "Rights Issue"). Each unit issued in the

Immunovia announces determined exercise price for warrants series TO 3

Thu, 27 Mar 2025 16:26:00 -0400

Immunovia carried out a rights issue of units during August – September 2024 (the "Rights Issue"). Each unit issued in the

Immunovia announces determined exercise price for warrants series TO 3

Thu, 27 Mar 2025 16:26:00 -0400

Immunovia carried out a rights issue of units during August – September 2024 (the "Rights Issue"). Each unit issued in the

Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test

Mon, 24 Mar 2025 11:31:00 -0400

LUND, Sweden, March 24, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results from the successful VERIFI study of its next-generation pancreatic cancer test, strengthening the company's position as it prepares to launch the pancreatic cancer blood test commercially.

Immunovia's next-generation test detected significantly more cancers than CA19-9, a common biomarker for pancreatic cancer, in the study. The company also announced that the specificity of its test in the VERIFI study was equivalent to CA19-9 and just below the target specificity

Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test

Mon, 24 Mar 2025 11:31:00 -0400

LUND, Sweden, March 24, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results from the successful VERIFI study of its next-generation pancreatic cancer test, strengthening the company's position as it prepares to launch the pancreatic cancer blood test commercially.

Immunovia's next-generation test detected significantly more cancers than CA19-9, a common biomarker for pancreatic cancer, in the study. The company also announced that the specificity of its test in the VERIFI study was equivalent to CA19-9 and just below the target specificity

Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test

Mon, 24 Mar 2025 11:31:00 -0400

LUND, Sweden, March 24, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results from the successful VERIFI study of its next-generation pancreatic cancer test, strengthening the company's position as it prepares to launch the pancreatic cancer blood test commercially.

Immunovia's next-generation test detected significantly more cancers than CA19-9, a common biomarker for pancreatic cancer, in the study. The company also announced that the specificity of its test in the VERIFI study was equivalent to CA19-9 and just below the target specificity

Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test

Mon, 24 Mar 2025 11:31:00 -0400

LUND, Sweden, March 24, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results from the successful VERIFI study of its next-generation pancreatic cancer test, strengthening the company's position as it prepares to launch the pancreatic cancer blood test commercially.

Immunovia's next-generation test detected significantly more cancers than CA19-9, a common biomarker for pancreatic cancer, in the study. The company also announced that the specificity of its test in the VERIFI study was equivalent to CA19-9 and just below the target specificity

Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test

Mon, 24 Mar 2025 11:31:00 -0400

LUND, Sweden, March 24, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results from the successful VERIFI study of its next-generation pancreatic cancer test, strengthening the company's position as it prepares to launch the pancreatic cancer blood test commercially.

Immunovia's next-generation test detected significantly more cancers than CA19-9, a common biomarker for pancreatic cancer, in the study. The company also announced that the specificity of its test in the VERIFI study was equivalent to CA19-9 and just below the target specificity